alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-10.1



 EXHIBIT 10.1 

AMENDMENT NO. 1 TO FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

AMENDMENT NO. 1 TO FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Amendment”) is dated and effective as of April 27,
2017, by and between Medallion Financial Corp. (the “Company”) and Alvin Murstein (the “Executive”). 
 WHEREAS, the
Company and the Executive are parties to that certain First Amended and Restated Employment Agreement, dated May 29, 1998 (the “Existing Agreement”); and 

WHEREAS, the Company and the Executive have agreed, subject to the terms and conditions of this Amendment, that the Existing Agreement be
amended to reflect certain agreed upon revisions to the terms of the Existing Agreement. 
 NOW THEREFORE, in consideration of the
foregoing and for other good and valuable consideration and with the intention of hereby being legally bound, the parties hereby agree as follows: 

1. Defined Terms. Except as otherwise indicated herein, all words and terms defined in the Existing Agreement shall have the same
meanings when used herein. 
 2. Amendment. Section 5.4(ii) of the Existing Agreement is hereby deleted in its entirety and replaced
with the following: 
 “Subject to subsection (iv) of this Section 5.4, in lieu of any further salary payments to the
Executive for periods subsequent to the Date of Termination, the Company shall pay as severance pay to the Executive a lump sum cash payment equal to the remainder of the salary, bonus and value of the fringe benefits which the Executive would be
entitled to receive for the balance of the Employment Period, which shall be calculated by multiplying the average of the Executive’s total salary, bonus and value of the fringe benefits for the prior three fiscal years by the fractional number
of years remaining on the Executive’s Employment Period.” 
 3. Limited Effect. Except as expressly amended and modified by
this Amendment, the Existing Agreement shall continue to be, and shall remain, in full force and effect in accordance with its terms. 
 4.
Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware. 
 [Signature
Page Follows.] 







 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the day and year set forth
above. 
  

			
	MEDALLION FINANCIAL CORP.
		
	 By:
	 	 /s/Larry D. Hall

		
	 Name:
	 	 Larry D. Hall

		
	 Title:
	 	 Senior Vice President & Chief Financial Officer

	
	ALVIN MURSTEIN
	
	 /s/Alvin Murstein



  
 2
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Commodity Futures Trading Commission

# TIME AND DATE:

11 a.m., March 19, 2010.

# PLACE:

1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room.

# STATUS:

Closed.

# MATTERS TO BE CONSIDERED:

Surveillance Matters.

# CONTACT PERSON FOR MORE INFORMATION:

Sauntia S. Warfield, 202-418-5084.

Sauntia S. Warfield,

Assistant Secretary of the Commission.

[FR Doc. 2010-3524 Filed 2-18-10; 4:15 pm]

BILLING CODE 6351-01-P
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[S. 1080 Introduced in Senate (IS)]

109th CONGRESS
  1st Session
                                S. 1080

  To amend the Safe Drinking Water Act to require the use of nontoxic 
products in the case of hydraulic fracturing that occurs during oil or 
                   natural gas production activities.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 19, 2005

    Mr. Jeffords (for himself, Mr. Lautenberg, Mrs. Boxer, and Mr. 
  Lieberman) introduced the following bill; which was read twice and 
       referred to the Committee on Environment and Public Works

_______________________________________________________________________

                                 A BILL

 
  To amend the Safe Drinking Water Act to require the use of nontoxic 
products in the case of hydraulic fracturing that occurs during oil or 
                   natural gas production activities.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Hydraulic Fracturing Safety Act of 
2005''.

SEC. 2. HYDRAULIC FRACTURING.

    Section 1421(d)(1) of the Safe Drinking Water Act (42 U.S.C. 
300h(d)(1)) is amended--
            (1) by adding at the end the following: ``The term 
        `underground injection' includes hydraulic fracturing, which 
        means the process of creating a fracture in a reservoir rock, 
        through the injection of fluids and propping agents, for the 
        purpose of reservoir stimulation relating to oil and gas 
        production activities.''; and
            (2) by adding at the end the following:
            ``(3) Hydraulic fracturing.--
                    ``(A) In general.--In the case of hydraulic 
                fracturing that occurs during the exploration for, or 
                the production of, oil or natural gas, a producer of 
                oil or natural gas shall not use diesel fuel or any 
                other material that the Administrator has listed as a 
                priority pollutant under the Federal Water Pollution 
                Control Act (33 U.S.C. 1251 et seq.).
                    ``(B) Regulations.--The Administrator shall 
                promulgate such regulations as are necessary--
                            ``(i) to regulate hydraulic fracturing in 
                        accordance with this subsection; and
                            ``(ii) to ensure that State programs under 
                        section 1422 or 1425 regulate hydraulic 
                        fracturing in accordance with this 
                        subsection.''.
                                 <all>
```
Editorial Note on Part 1315
Editorial Note: Nomenclature changes to part appear at 82 FR 97041, Dec. 30, 2016.

§ 1315.24 Inventory allowance for individual manufacturing quotas. ( a ) For the purpose of determining individual manufacturing quotas pursuant to § 1315.23, each registered manufacturer shall be allowed as part of such quota an amount sufficient to maintain an inventory: ( 1 ) For current manufacturers, 40 percent of their average estimated net disposal for the current calendar year and the last preceding calendar year; or
( 2 ) For new manufacturers, 40 percent of their reasonably estimated net disposal for the next calendar year as determined by the Administrator.
( b ) During each calendar year, each registered manufacturer receiving a manufacturing quota shall be allowed to maintain an inventory of a chemical not exceeding 55 percent of their estimated net disposal of that chemical for that year, as determined at the time his quota for that year was determined. At any time the inventory of a chemical held by a manufacturer exceeds 55 percent of their estimated net disposal, their quota for that chemical is automatically suspended and shall remain suspended until their inventory is less than 50 percent of his estimated net disposal. The Administrator may, upon application and for good cause shown, permit a manufacturer whose quota is, or is likely to be, suspended pursuant to this paragraph to continue manufacturing and to accumulate an inventory in excess of 55 percent of their estimated net disposal, upon such conditions and within such limitations as the Administrator may find necessary or desirable.
( c ) If, during a calendar year, a registrant has manufactured the entire quantity of a chemical allocated to them under an individual manufacturing quota, and their inventory of that chemical is less than 30 percent of his estimated net disposal of that class for that year, the Administrator may, upon application pursuant to § 1315.25, increase the quota of such registrant sufficiently to allow restoration of the inventory to 40 percent of the estimated net disposal for that year.
[88 FR 60143, Aug. 31, 2023]
SHAREN WILSON

.Criminal District Attorney 

Tarrant County

July 13, 2015

Hon. Abel Acosta, Clerk

Texas Court of Criminal Appeals

Re: Ex parte Rodney Elnesto Smiley, Nos. WR-31,454-03; C-213-

010293-1011284-B.

Dear Hon. Acosta: 

On April 29, 2015, this Court invited Tarrant County (“the State”) 

to brief two issues in the above case. The brief, if filed, was ordered due 

by June 29, 2015. 

On June 29, 2015, the State requested a two week extension for 

which to file a brief. The State’s brief is currently due today, July 13, 

2015.

After the State requested the extension, and indicated its desire to 

file a State’s brief, the Texas Department of Criminal Justice (“TDCJ”)

filed a brief. TDCJ’s brief sufficiently addresses the Court’s questions 

and the State has nothing to add. Therefore, the State will be filing 

WR-31,454-03

COURT OF CRIMINAL APPEALS

AUSTIN, TEXAS

Transmitted 7/13/2015 10:16:44 AM

Accepted 7/13/2015 11:38:16 AM

ABEL ACOSTA

CLERK
nothing further unless directed by the Court.

Based on everything already filed, the State prays that this Court 

dismiss the application of Rodney Elnesto Smiley as moot or, in the 

alternative, deny him relief.

Respectfully submitted, 

SHAREN WILSON

Criminal District Attorney

Tarrant County, Texas

/s/ Andréa Jacobs_______ 

DEBRA WINDSOR, Assistant ANDRÉA JACOBS, Assistant

Criminal District Attorney Criminal District Attorney

Chief, Post-Conviction State Bar No. 24037596

401 W. Belknap Street

Fort Worth, Texas 76196-0201

(817) 884-1687

FAX (817) 884-1672

coaappellatealerts@tarrantcounty.com

CERTIFICATE OF SERVICE

A true copy of the State’s letter has been sent, via electronic mail, 

to Smiley’s attorney, Hon. Kenneth Nash, at Ken.Nash@tdcj.texas.gov 

and TDCJ’s attorney, Hon. Joseph Corcoran, at 

Joseph.Corcoran@TexasAttorneyGeneral.gov on this 13th day of July

2015.

/s/ Andréa Jacobs

ANDRÉA JACOBS
I i I 

### SERVED: HJLY 15, 2013
;

U.S. DEPARTMENT**OF~TRANSPORTATION** OFFICE OF HEARINGS WASHINGTON, DC

IN THE MATTER OF i TRANS NORTH AVIATION, LTD. i FAA DOCKET No. [TO BE ASSIGNED] (Civil Penalty Action) FDMS No. FAA-;2013-0046



### ORDERGRANTING MOTION TOTAKEJUDICIAL NOTICE
OnJuly 11, 2013, Complainant Federal Aviation Administration ("Complainant") filed under 14 C.P.R. §13.218 a Motion Requesting Judicial Notice ("Motion"). The Motion encompasses 50 Fed.Reg. 29306-01, dated July 18)1985, the Final Rule on 14 C.P.R. §135.267(d), as well as amendments thereto at 54 Fed.Reg. 39288-01 (September 25, 1989) and 61 Fed.Reg. 2608-01 (January 26, 1996). Respondent Trans North Aviation, Ltd. has not filed an answerto the Motion to date. The Court may take Judicial Notice ofa fact which is not subjectto reasonable dispute in that it is either (1) generally known withinthe territorialjurisdiction ofthe trial court or (2) capable ofaccurate and ready determination by resbrt to sources whose accuracy cannot2 reasonably be questioned. 1 The matters for which Complainant seeks Judicial Notice are published rules ofa federal agency. These matters are capable ofaccurate and•ready determinationbyresort to sources whose accuracy cannotreasonably be questioned. They also are matters within the public domain. WHEREFORE, Complainant's Motion having been read and considered, it is hereby ORDERED that Judicial Notice be and is herebytaken ofthe following: 1. 50 Fed.Reg. 29306-01, July 18, 1985; : 2. 54 Fed.Reg. 39288-01, September 25, 1989; and 3. 61 Fed.Reg. 2608-01, January 26, 1996.

1 Federal Rules of Evidence, Rule 201 (28 U.S.C.) RichardC. Goodwin Administrative Law Judge3

SERVICE LIST ' ORIGINAL & 

## loNE COPY Federal Aviation Administration 800 Independence Avenue, S.W. Washington, DC 20591 Attention: Hearing Docket Clerk, AGC-430

. Wilbur Wright Building-Suite

### 2~1000**1** ONE COPY Charles R. Barnett III, Respondent's Counsel Barnett & Borth, LLC 800 Waukegan Road, Suite 200 Glenview, IL 60025 TEL: 847-809-9520 FAX: 815-356-7042 Jeanette B. Daubaras, Complainant's Counsel Office ofthe Regional Counsel, Great Lakes Region Federal Aviation Administration · 2300 East DevonAvenue Des Plaines, AL 60018 TEL: 847-294-7313 FAX: 847-294-7498

I The Honorable Richard C. Goodwin,AdministrativeLawJudge Office ofHearings, M-20 ' U.S. Department ofTransportation 1200 NewJersey Avenue, S.E. (E11-310) Washington, DC 20590 TEL: 202-366-2139 Attorney-Advisor 202-366-5121 StaffAssistant FAX: 202-366-7536 FDMS No. FAA-2013-0046 (Civil Penalty Action)

1 Service was by U.S. Mail. For service in person orby bxpedited courier, use the following address: Federal Aviation Administration, 600 Independence Avenue, S.W., Wilbur Wright Building-Suite 2WIOOO, Washington, DC 20591, Attention: Hearing Docket Clerk, AGC-430. 

### !
[No. 39246-8-I.

Division One.

January 12, 1998.]

#### The State of Washington, *Respondent,*v. Kenneth Lyle Westmark, *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 94-1-06810-1, Patricia H. Aitken, J., entered October 17, 1996; August 9, 1996. *Affirmed*by unpublished opinion per Ellington, J., concurred in by Baker, C.J., and Kennedy, J.
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.862 Oleic acid derived from tall oil fatty acids. The food additive oleic acid derived from tall oil fatty acids may be safely used in food and as a component in the manufacture of food-grade additives in accordance with the following prescribed conditions: ( a ) The additive consists of purified oleic acid separated from refined tall oil fatty acids.
( b ) The additive meets the following specifications: ( 1 ) Specifications for oleic acid prescribed in the Food Chemicals Codex, 7th ed. (2010), pp. 743-744, which is incorporated by reference, except that titer (solidification point) shall not exceed 13.5 °C and unsaponifiable matter shall not exceed 0.5 percent. The Director of the Office of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain copies from the United States Pharmacopeial Convention, 12601 Twinbrook Pkwy., Rockville, MD 20852 (Internet address *http://www.usp.org*). Copies may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030 or go to: *http://www.archives.gov/federal-register/cfr/ibr-locations.html .*
( 2 ) The resin acid content does not exceed 0.01 as determined by ASTM method D1240-82, “Standard Test Method for Rosin Acids in Fatty Acids,” which is incorporated by reference. Copies may be obtained from the American Society for Testing Materials, 100 Barr Harbor Dr., West Conshohocken, Philadelphia, PA 19428-2959, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( 3 ) The requirements for absence of chick-edema factor as prescribed in § 172.860.
( c ) It is used or intended for use as follows: ( 1 ) In foods as a lubricant, binder, and defoaming agent in accordance with good manufacturing practice.
( 2 ) As a component in the manufacture of other food-grade additives.
( d ) To assure safe use of the additive, the label and labeling of the additive and any premix thereof shall bear, in addition to the other information required by the Act, the following: ( 1 ) The common or usual name of the acid.
( 2 ) The words “food grade” in juxtaposition with and equally as prominent as the name of the acid.
[42 FR 14491, Mar. 15, 1977, as amended at 49 FR 10105, Mar. 19, 1984; 78 FR 71465, Nov. 29, 2013; 88 FR 17721, Mar. 24, 2023]
[Federal Register Volume 75, Number 36 (Wednesday, February 24, 2010)]
[Notices]
[Page 8373]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3748]



[[Page 8373]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the National 
Cancer Institute Board of Scientific Advisors, March 8, 2010, 8 a.m. to 
March 9, 2010, 12 p.m., National Institutes of Health, Building 31, 31 
Center Drive, Bethesda, MD 20892 which was published in the Federal 
Register on January 20, 2010, 75FR3243.
    This Federal Register Notice is amended to change the meeting to a 
one day meeting to be held on March 8, 2010, 8 a.m. to 6 p.m. The 
meeting is open to the public.

    Dated: February 18, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-3748 Filed 2-23-10; 8:45 am]
BILLING CODE 4140-01-P
Editorial Note on Part 189
Editorial Note: Nomenclature changes to part 189 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 70 FR 40880, July 15, 2005; and 70 FR 67651, Nov. 8, 2005.

§ 189.1 Substances prohibited from use in human food. ( a ) The food ingredients listed in this section have been prohibited from use in human food by the Food and Drug Administration because of a determination that they present a potential risk to the public health or have not been shown by adequate scientific data to be safe for use in human food. Use of any of these substances in violation of this section causes the food involved to be adulterated in violation of the act.
( b ) This section includes only a partial list of substances prohibited from use in human food, for easy reference purposes, and is not a complete list of substances that may not lawfully be used in human food. No substance may be used in human food unless it meets all applicable requirements of the act.
( c ) The Commissioner of Food and Drugs, either on his own initiative or on behalf of any interested person who has submitted a petition, may publish a proposal to establish, amend, or repeal a regulation under this section on the basis of new scientific evaluation or information. Any such petition shall include an adequate scientific basis to support the petition, pursuant to part 10 of this chapter, and will be published for comment if it contains reasonable grounds.
[42 FR 14659, Mar. 15, 1977, as amended at 54 FR 24899, June 12, 1989]
<PAGE>   1
                                                                   EXHIBIT 23.05


Board of Directors
Corixa Corporation
1124 Columbia Street, Suite 200
Seattle, WA  98104-2040

Members of the Board:

        We hereby consent to the inclusion of our opinion letter to the Board of
Directors of Corixa Corporation as Appendix B to the proxy statement/prospectus
of Corixa Corporation constituting a part of the Registration Statement on Form
S-4 relating to the proposed merger transaction involving Corixa and Ribi
ImmunoChem Research, Inc. and references thereto in such proxy
statement/prospectus under the captions "SUMMARY - Opinion of Corixa's Financial
Advisor", "THE MERGER - Recommendation of Corixa's Board; Corixa's Reasons for
the Merger", and "THE MERGER - Opinion of Corixa's Financial Advisor". In giving
such consent, we do not admit that we come within the category of persons whose
consent is required under, and we do not admit that we are "experts" for
purposes of, the Securities Act of 1993, as amended, and the rules and
regulations promulgated thereunder.



                                            PACIFIC GROWTH EQUITIES, INC.

                                            /s/ George J. Millstein
                                            ----------------------------------
                                            George J. Millstein
Editorial Note on Part 25
Editorial Note: Nomenclature changes to part 25 appear at 88 FR 45065, July 14, 2023.

§ 25.31 Human drugs and biologics. The classes of actions listed in this section are categorically excluded and, therefore, ordinarily do not require the preparation of an EA or an EIS: ( a ) Action on an NDA, abbreviated application, application for marketing approval of a biologic product, or a supplement to such applications, or action on an OTC monograph, if the action does not increase the use of the active moiety.
( b ) Action on an NDA, abbreviated application, or a supplement to such applications, or action on an OTC monograph, if the action increases the use of the active moiety, but the estimated concentration of the substance at the point of entry into the aquatic environment will be below 1 part per billion.
( c ) Action on an NDA, abbreviated application, application for marketing approval of a biologic product, or a supplement to such applications, or action on an OTC monograph, for substances that occur naturally in the environment when the action does not alter significantly the concentration or distribution of the substance, its metabolites, or degradation products in the environment.
( d ) Withdrawal of approval of an NDA or an abbreviated application.
( e ) Action on an IND.
( f ) Testing and release by the Food and Drug Administration of lots or batches of a licensed biologic product.
( g ) Establishment of bioequivalence requirements for a human drug or a comparability determination for a biologic product subject to licensing.
( h ) Issuance, revocation, or amendment of a standard for a biologic product.
( i ) Revocation of a license for a biologic product.
( j ) Action on an application for marketing approval for marketing of a biologic product for transfusable human blood or blood components and plasma.
[62 FR 40592, July 29, 1997, as amended at 63 FR 26697, May 13, 1998; 64 FR 399, Jan. 5, 1999; 70 FR 14980, Mar. 24, 2005]